NRAS Q61H

Clinical trials for NRAS Q61H explained in plain language.

Never miss a new study

Get alerted when new NRAS Q61H trials appear

Sign up with your email to follow new studies for NRAS Q61H, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Trials to join now! 1

New targeted drug hopes to shrink NRAS-Driven cancers

Disease control Recruiting now

This early-phase study tests a new oral drug, RLY-8161, designed to block a specific cancer-driving protein called NRAS. It is for people with advanced melanoma or other solid tumors that have an NRAS mutation and have not responded to standard treatments. The main goals are to f…

Matched conditions: NRAS Q61H

Phase 1 • Sponsor: Relay Therapeutics, Inc. • Aim: Disease control

Last updated Jul 04, 2026 00:00 UTC

NRAS Q61H

Get alerted when new NRAS Q61H trials appear

New targeted drug hopes to shrink NRAS-Driven cancers